Great news at the beginning of 2023! Together with our American partner, we received FDA approval, 510(k) in the field of ophthalmology, for the commercialization of a reticulated hyaluronic acid gel, indicated in the indication of dry eye, disease that affects more than 16 million people in the United States and is the second most common cause for patients to consult their eye care professional. This innovative treatment proved its effectiveness in a clinical study in the United States, promising a great success in the market of ophthalmology. Jean-Paul Gerardin, CEO of Symatese states “this registration reinforces our international deployment, demonstrating the ability of our teams to develop innovative solutions, for the benefit of physicians and patients, especially in the field of hyaluronic acids and injection systems”
First authorization in the USA of the HA Symatese technology
- 18 January 2023
